{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:07:03Z","timestamp":1763662023468,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007091","name":"RefleXion Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Biology-guided radiotherapy (BgRT) uses real-time functional imaging to guide radiation therapy treatment. Positron emission tomography (PET) tracers targeting prostate-specific membrane antigen (PSMA) are superior for prostate cancer detection than conventional imaging. This study aims at describing nodal and distant metastasis distribution from prostate cancer and at determining the proportion of metastatic lesions suitable for BgRT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single-institution patient subset from the ProPSMA trial (ID ACTRN12617000005358) was analysed. Gross tumour volumes (GTV) were delineated on the CT component of a PSMA PET\/CT scan. To determine the suitability of BgRT tracking zones, the normalized SUV (nSUV) was calculated as the ratio of SUVmax inside the GTV to the SUVmean of adjacent three-dimensional shells of thickness 5 mm\/10 mm\/20 mm as a measure of signal to background contrast. Targets were suitable for BgRT if (1) nSUV was larger than an nSUV threshold and (2) non-tumour tissue inside adjacent shell was free of PET-avid uptake.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of this cohort of 84 patients, 24 had at least one pelvic node or metastatic site disease, 1 to 13 lesions per patient, with a total of 98 lesions (60 pelvic nodes\/38 extra-pelvic nodal diseases and haematogenous metastases). Target volumes ranged from 0.08 to 9.6 cm<jats:sup>3<\/jats:sup> while SUVmax ranged from 2.1 to 55.0. nSUV ranged from 1.9 to 15.7\/2.4 to 25.7\/2.5 to 34.5 for the 5 mm\/10 mm\/20 mm shell expansion. Furthermore, 74%\/68%\/34% of the lesions had nSUV \u2265 3 and were free of PSMA PET uptake inside the GTV outer shell margin expansion of 5 mm\/10 mm\/20 mm. Adjacent avid organs were another lesion, bladder, bowel, ureter, prostate, and liver.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The majority of PSMA PET\/CT-defined radiotherapy targets would be suitable for BgRT by using a 10-mm tracking zone in prostate cancer. A subset of lesions had adjacent non-tumour uptake, mainly due to the proximity of ureter or bladder, and may require exclusion from emission tracking during BgRT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.854589","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T09:43:09Z","timestamp":1649756589000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Mathieu","family":"Gaudreault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Hardcastle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Price","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Kron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard G.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/53\/12\/R01","article-title":"Anatomical Imaging for Radiotherapy","volume":"53","author":"Evans","year":"2008","journal-title":"Phys Med Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2007.11.023","article-title":"A (Short) History of Image-Guided Radiotherapy","volume":"86","author":"Verellen","year":"2008","journal-title":"Radiother Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/54\/1\/R01","article-title":"Biological Imaging in Radiation Therapy: Role of Positron Emission Tomography","volume":"54","author":"Nestle","year":"2009","journal-title":"Phys Med Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctro.2021.04.003","article-title":"The Technical Design and Concept of a PET\/CT Linac for Biology-Guided Radiotherapy","volume":"29","author":"Oderinde","year":"2021","journal-title":"Clin Trans Radiat Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20200873","article-title":"Biology-Guided Radiotherapy: Redefining the Role of Radiotherapy in Metastatic Cancer","volume":"94","author":"Shirvani","year":"2021","journal-title":"Br J Radiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1053\/j.semnuclmed.2013.10.008","article-title":"Molecular Imaging of Urogenital Diseases","volume":"44","author":"Cho","year":"2014","journal-title":"Semin Nucl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13397","article-title":"68Ga-PSMA has a High Detection Rate of Prostate Cancer Recurrence Outside the Prostatic Fossa in Patients Being Considered for Salvage Radiation Treatment","volume":"117","author":"van Leeuwen","year":"2016","journal-title":"BJU Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","article-title":"Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy","volume":"58","author":"Eiber","year":"2017","journal-title":"J Nucl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2018.03.016","article-title":"Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging","volume":"45","author":"Hofman","year":"2018","journal-title":"Urol Clinics North America"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-Specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls","volume":"38","author":"Hofman","year":"2018","journal-title":"Radiographics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrurol.2016.175","article-title":"And Treatment Considerations","volume":"14","author":"Tosoian","year":"2018","journal-title":"Nat Rev Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 Prostate-Specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer\u2014Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-Specific Membrane Antigen-Avid Lesions: A Systematic Review and Meta-","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4573","article-title":"Diagnostic Performance of 18 F-DCFPyL-PET\/CT in Men With Biochemically Recurrent Prostate Cancer: Results From the CONDOR Phase III, Multicenter Study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.11.031","article-title":"Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate Cancer","volume":"82","author":"Jereczek-Fossa","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Radiat Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.07.009","article-title":"Metastasis-Directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-Institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy","volume":"76","author":"de Bleser","year":"2019","journal-title":"Eur Urol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic Ablative Radiotherapy Versus Standard of Care Palliative Treatment in Patients With Oligometastatic Cancers (SABR-COMET): A Randomised, Phase 2, Open-Label Trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET-10): Study Protocol for a Randomized Phase III Trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100734","article-title":"Can Polymetastatic Disease Be ARRESTed Using SABR? A Dosimetric Feasibility Study to Inform Development of a Phase 1 Trial","volume":"6","author":"Corkum","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1118\/1.4761951","article-title":"Emission Guided Radiation Therapy for Lung and Prostate Cancers: A Feasibility Study on a Digital Patient","volume":"39","author":"Fan","year":"2012","journal-title":"Med Phys"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1118\/1.4861816","article-title":"The Potential of Positron Emission Tomography for Intratreatment Dynamic Lung Tumor Tracking: A Phantom Study","volume":"41","author":"Yang","year":"2014","journal-title":"Med Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2019.10.006","article-title":"Online Prostate-Specific Membrane Antigen and Positron Emission Tomography\u2013Guided Radiation Therapy for Oligometastatic Prostate Cancer","volume":"5","author":"Hrinivich","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14374","article-title":"A Prospective Randomized Multicentre Study of the Impact of Gallium-68 Prostate-Specific Membrane Antigen (PSMA) PET\/CT Imaging for Staging High-Risk Prostate Cancer Prior to Curative-Intent Surgery or Radiotherapy (proPSMA Study): Clinical Trial Protocol","volume":"122","author":"Hofman","year":"2018","journal-title":"BJU Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-Specific Membrane Antigen PET-CT in Patients With High-Risk Prostate Cancer Before Curative-Intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"B27","article-title":"[68ga]Ga-PSMA-11 in Prostate Cancer: A Comprehensive Review","volume":"10","author":"Bois","year":"2020","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"B28","doi-asserted-by":"publisher","first-page":"137.1-11","DOI":"10.1186\/s13244-020-00926-y","article-title":"Lesion-To-Background Ratio Threshold Value of SUVmax of Simultaneous [68Ga]Ga-PSMA-11 PET\/MRI Imaging in Patients With Prostate Cancer","volume":"11","author":"Zhao","year":"2020","journal-title":"Insights Into Imaging"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.202861","article-title":"Accuracy of Dose Calibrators for 68Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment","volume":"59","author":"Bailey","year":"2018","journal-title":"J Nucl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients With Intermediate to High Risk Prostate Cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J\u00a0Urol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3952-0","article-title":"Advantage of 18F-PSMA-1007 Over 68Ga-PSMA-11 PET Imaging for Differentiation of Local Recurrence vs. Urinary Tracer Excretion","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.246363","article-title":"Diagnostic Accuracy of 18F-PSMA-1007 PET\/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence","volume":"62","author":"Sprute","year":"2021","journal-title":"J Nucl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04635-7","article-title":"Prospective Study on the Effect of Short-Term Androgen Deprivation Therapy on PSMA Uptake Evaluated With 68Ga-PSMA-11 PET\/MRI in Men With Treatment-Na\u00efve Prostate Cancer","volume":"47","author":"Ettala","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","article-title":"Influence of Androgen Deprivation Therapy on PSMA Expression and PSMA-Ligand PET Imaging of Prostate Cancer Patients","volume":"47","author":"Vaz","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.854589\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T09:43:11Z","timestamp":1649756591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.854589\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":35,"alternative-id":["10.3389\/fonc.2022.854589"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.854589","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"article-number":"854589"}}